Computational investigation of potential natural compounds as inhibitors of monkeypox virus cysteine proteinase.

Front Bioinform

Biological and Bio-computational Lab, Department of Life Science, Sharda School of Bio-Science and Technology, Sharda University, Greater Noida, Uttar Pradesh, India.

Published: July 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Introduction: Monkeypox is a serious viral illness that is rarely seen but is spread from person to person and from animals to humans. Cysteine proteinase, an essential enzyme involved in the replication of the monkeypox virus (MPXV), is one of many possible therapeutic targets for MPXV. The primary function of this enzyme is to cleave the precursor polyprotein into the distinct proteins required for viral assembly. The aim was to develop potential drugs that can inhibit the proteinase and stop the spread of the MPXV.

Methods: Virtual screening, molecular docking, molecular dynamics simulation, and free binding energy calculations were used to explore the potential of 569 phytochemicals from a variety of plants that could inhibit the proteinase of the MPXV.

Results: The four compounds (Unii-CQ2F5O6yiy, lithospermic acid, kaempferol, and rhamnocitrin) with the best docking scores displayed docking score values ranging from -9.5 to -7.4 kcal/mol and were used for further analysis. Out of these, Unii-CQ2F5O6yiy exhibited a docking score of -9.5 kcal/mol, indicating the highest binding to the proteinase. Unii-CQ2F5O6yiy had the most stable and consistent root mean square deviation (RMSD) of <3 Å.

Discussion: We identified the top four phytochemicals that exhibited better docking scores than the reference compound. The RMSDs of proteins in all the phytochemical complexes exhibited acceptable deviation except for lithospermic acid, whereas atoms of Unii-CQ2F5O6yiy and kaempferol in their docked complexes displayed less fluctuation than the reference compound (<5.4 Å).

Conclusion: Unii-CQ2F5O6yiy could be used as a potential antiviral agent for the management of monkeypox virus. However, further experimental validation under and conditions is required to confirm its antiviral activity against MPXV.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12336155PMC
http://dx.doi.org/10.3389/fbinf.2025.1637207DOI Listing

Publication Analysis

Top Keywords

monkeypox virus
8
cysteine proteinase
8
inhibit proteinase
8
docking score
8
proteinase
5
computational investigation
4
investigation potential
4
potential natural
4
natural compounds
4
compounds inhibitors
4

Similar Publications

A Dual-Target Real-time PCR for proactive detection of Mpox variants.

J Virol Methods

September 2025

British Columbia Centre for Disease Control Public Health Laboratory, Vancouver, British Columbia, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address:

In 2022, cases of Monkeypox virus (MPXV) in California contained a mutation in the TNF receptor gene (GR2G) that rendered the virus undetectable using a widely adopted public health diagnostic qPCR assay. This underscored the need for a dual-target PCR approach and prompted validation of a second target by the BCCDC Public Health Laboratory. In addition to the GR2G target validated in the original qPCR assay (and duplexed with the endogenous target human β-globin (HBG)), GP113 (OPG128) was identified and validated using both clinical samples and MPXV DNA controls.

View Article and Find Full Text PDF

Genomic epidemiology of clade Ia monkeypox viruses circulating in the Central African Republic in 2022-24: a retrospective cross-sectional study.

Lancet Microbe

September 2025

Institut Pasteur de Bangui, Bangui, Central African Republic; Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon. Electronic address:

Background: The spread of monkeypox virus (Orthopoxvirus monkeypox) clade Ib from the Democratic Republic of the Congo to neighbouring countries has raised global concerns, leading to WHO declaring mpox a public health emergency on Aug 14, 2024. We applied genomic epidemiology to investigate the causes of recurrent mpox outbreaks in the Central African Republic. We aimed to determine whether frequent zoonotic spillovers or increased human-to-human transmissions are driving mpox epidemiology.

View Article and Find Full Text PDF

Remarkable photodynamic activity of tetra-cationic porphyrins against Vaccinia virus and Monkeypox virus.

Antiviral Res

September 2025

Setor de Virologia, Departamento de Medicina Veterinária Preventiva, Universidade Federal de Santa Maria, Brazil; Programa de Pós-graduação em Medicina Veterinária, Departamento de Medicina Veterinária Preventiva, Universidade Federal de Santa Maria, Brazil. Electronic address: eduardofurtadof

In this context, we evaluated the photodynamic effects of four cationic tetra-(pyridyl)porphyrins against Vaccinia virus Western Reserve (VACV WR) and Monkeypox virus (MPXV). The porphyrins were initially analyzed for cytotoxicity to Vero cells by MTT assay and the maximal non-cytotoxic concentrations were used in virucidal assays. For virucidal assays, VACV-WR (107.

View Article and Find Full Text PDF

Background: Limited mpox vaccination coverage, declining cross-protection from historical smallpox vaccination campaigns, and persistent zoonotic reservoirs leave many sub-Saharan countries susceptible to mpox outbreaks. With millions of vaccine doses made available to the region since late 2024 and the absence of country-specific guidelines for allocation, estimating the country-specific impact of one-time mass vaccination strategies is necessary for ongoing outbreaks and other countries at future risk.

Methods And Findings: We adapted a next generation matrix model to project disease transmission potential for 47 sub-Saharan countries from 2025 to 2050 under four transmission scenarios with different contributions of community versus sexual contacts.

View Article and Find Full Text PDF

In 2022, the presumption of monkeypox (mpox) to be of limited epidemiology shifted when a global outbreak was announced. Being a member of the Orthopoxvirus genus in the Poxviridae family, it'd been reported in over 82 countries with over 17 000 confirmed cases by July 2022, thus showing its capability for spreading rapidly. As the smallpox vaccine offers 85% cross-immunity against mpox, the outbreak highlighted the attenuation of global immunity against orthopoxviruses after the cessation of vaccination campaigns against smallpox.

View Article and Find Full Text PDF